ATE411029T1 - Estrogene als antimitotika - Google Patents

Estrogene als antimitotika

Info

Publication number
ATE411029T1
ATE411029T1 AT05016659T AT05016659T ATE411029T1 AT E411029 T1 ATE411029 T1 AT E411029T1 AT 05016659 T AT05016659 T AT 05016659T AT 05016659 T AT05016659 T AT 05016659T AT E411029 T1 ATE411029 T1 AT E411029T1
Authority
AT
Austria
Prior art keywords
antimitotics
estrogens
arthritis
methoxyestradiol
behcet
Prior art date
Application number
AT05016659T
Other languages
English (en)
Inventor
Amato Robert John D
Moses Judah Folkman
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Application granted granted Critical
Publication of ATE411029T1 publication Critical patent/ATE411029T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096—Alkynyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05016659T 1993-08-06 1994-08-02 Estrogene als antimitotika ATE411029T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/102,767 US5504074A (en) 1993-08-06 1993-08-06 Estrogenic compounds as anti-angiogenic agents

Publications (1)

Publication Number Publication Date
ATE411029T1 true ATE411029T1 (de) 2008-10-15

Family

ID=22291581

Family Applications (2)

Application Number Title Priority Date Filing Date
AT94924120T ATE313327T1 (de) 1993-08-06 1994-08-02 Östrogene verbindungen als antiangiogenese wirkstoffe
AT05016659T ATE411029T1 (de) 1993-08-06 1994-08-02 Estrogene als antimitotika

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT94924120T ATE313327T1 (de) 1993-08-06 1994-08-02 Östrogene verbindungen als antiangiogenese wirkstoffe

Country Status (11)

Country Link
US (8) US5504074A (de)
EP (3) EP1927359A3 (de)
JP (3) JPH09501433A (de)
AT (2) ATE313327T1 (de)
AU (1) AU7450994A (de)
CA (1) CA2168850C (de)
DE (2) DE69434584T2 (de)
DK (2) DK1640009T3 (de)
ES (2) ES2315763T3 (de)
PT (1) PT1640009E (de)
WO (1) WO1995004535A1 (de)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214807A1 (en) * 1993-08-06 2004-10-28 D'amato Robert J. Estrogenic compounds as anti-mitotic agents
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US6908910B2 (en) * 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
WO1996040150A1 (en) * 1995-06-07 1996-12-19 Merck & Co., Inc. Treatment and prevention of prostatic disease
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US20030195180A1 (en) * 1995-12-12 2003-10-16 D'amato Robert John Estrogenic compounds as anti-mitotic agents
CN1245982C (zh) 1996-05-09 2006-03-22 阿姆瑞德手术有限公司 哮喘和气道疾病的治疗
EP1806131A3 (de) * 1996-07-22 2007-08-01 Renovo Limited Verwendung von Sex-Steroid-Funktionsmodulatoren zur Behandlung von Wunden und fibrotischen Erkrankungen
US5958892A (en) 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
US5801012A (en) 1996-09-17 1998-09-01 Northwestern University Methods and compositions for generating angiostatin
DE19654750A1 (de) * 1996-12-30 1998-07-02 Helmut Dr Med Zander Verwendung von Wirkstoffen mit Östrogen-Wirkung zur Vorbeugung und Behandlung von Makuladegeneration
WO1998040077A1 (en) * 1997-03-11 1998-09-17 Allergan Sales, Inc. Anti-angiogenic agents
EP1003498A4 (de) 1997-03-26 2004-07-14 Biosource Tech Inc Diaylether und deren derivate wie antikrebs-verbindungen
US6207704B1 (en) 1997-06-09 2001-03-27 Massachusetts Institute Of Technology Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof
US20020002294A1 (en) * 1997-09-24 2002-01-03 D' Amato Robert J. Estrogenic compounds as antiangiogenic agents
US6355630B1 (en) 1997-10-23 2002-03-12 American Home Products Corporation Estra-1,3,5(10)-triene-7α-thioethers
US6689768B2 (en) * 1998-04-15 2004-02-10 Jenapharm Gmbh & Co. Kg Pharmaceutical preparations for treating side effects during and/or after GnRHa therapy
CA2333147C (en) 1998-07-13 2012-02-07 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
ID28791A (id) * 1998-08-07 2001-07-05 Endorech Inc PENGHAMBATAN DEHIDROGENASE HIDROKSISTEROID 3α TIPE 3
EP1124545B1 (de) 1998-08-11 2004-12-15 EntreMed, Inc. Verwendung von 2-methoxyestradiol als fungizide
SI1107795T1 (en) 1998-09-04 2003-06-30 The Regents Of The University Of Michigan Thiomolybdate associated with at least one carbohydrate, and its use for preventing or treating diseases characterized by aberrant vascularization, such as cancer, wet type macular degeneration, rheumatoid arthritis
WO2000050067A1 (en) * 1999-02-26 2000-08-31 Saltech I Göteborg Ab Method and composition for the regulation of hepatic and extrahepatic production of insulin-like growth factor-1
US7087592B1 (en) * 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
AU7572600A (en) * 1999-08-23 2001-03-19 Entremed, Inc Methods of obtaining 2-methoxyestradiol of high purity
PT1955700E (pt) 1999-09-30 2011-05-04 Harbor Biosciences Inc Tratamento terap?utico de doen?as associadas ao receptor de androg?nios
AUPQ342599A0 (en) 1999-10-14 1999-11-04 University Of Melbourne, The Conjugates and uses thereof
US6696436B1 (en) 1999-10-26 2004-02-24 The United States Of America As Represented By The Department Of Health And Human Services B-homoestra-1,3,5(10)-trienes as modulators of tubulin polymerization
US6518261B2 (en) * 2000-03-17 2003-02-11 Oncology Sciences Corporation Use of eugenol in combination with other chemopreventative agents as prophylaxis for cancers
US6995278B2 (en) * 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
US20050192258A1 (en) * 2000-08-18 2005-09-01 Agoston Gregory E. Antiangiogenic agents
EP1343803A2 (de) * 2000-11-27 2003-09-17 EntreMed, Inc. 2-substituierte estrogene mit antiangiogenischer aktivität
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
US7037906B1 (en) * 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
US6632835B2 (en) 2001-02-22 2003-10-14 Nanodesign Inc. Dibenzo[c]chromen-6-one derivatives as anti-cancer agents
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US6593321B2 (en) 2001-06-11 2003-07-15 Southwest Foundation For Biomedical Research 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity
US20040229960A1 (en) * 2001-07-13 2004-11-18 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
JP2004536847A (ja) * 2001-07-13 2004-12-09 オキシジーン， インコーポレイテッド 眼の疾患の処置のためのチューブリン結合薬剤を投与するための組成物および方法
US7488723B2 (en) * 2001-09-05 2009-02-10 Alcon, Inc. Use of non-feminizing estrogens as treatment for retinal vascular diseases
WO2003028840A2 (en) * 2001-09-27 2003-04-10 Board Of Regents, The University Of Texas System Combined compositions and methods for tumor vasculature coagulation and treatment
US20080279936A1 (en) * 2001-10-10 2008-11-13 The University Of Pittsburgh Estradiol metabolites for reduction of endothelin production
US7023931B2 (en) * 2001-11-05 2006-04-04 Texas Instruments Incorporated System and method for soft slicing
US7179798B2 (en) * 2001-11-16 2007-02-20 Russell R. Roby Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions
WO2003063787A2 (en) * 2002-01-30 2003-08-07 Entremed, Inc. Non-steroidal analogs of 2-methoxyestradiol
WO2003073985A2 (en) * 2002-03-01 2003-09-12 Entremed, Inc. New methods of using antiangiogenic agents
EP1539799B1 (de) * 2002-06-21 2013-12-11 The University of Utah Research Foundation Quervernetzte verbindungen und verfahren zu deren herstellung und anwendung
KR20120068769A (ko) 2002-07-15 2012-06-27 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 음이온성 인지질 및 아미노인지질에 결합하는 선택된 항체 및 치료하는데 있어서 이의 용도
US7335362B2 (en) * 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
US7335735B2 (en) * 2003-05-07 2008-02-26 Cedars-Sinai Medical Center Intracellular estradiol binding protein
CN101137388A (zh) 2003-05-15 2008-03-05 犹他卅大学研究基金会 抗粘连复合材料及其应用方法
EP1633367A2 (de) * 2003-05-28 2006-03-15 EntreMed, Inc. Antiangiogene mittel
US20050032766A1 (en) * 2003-08-05 2005-02-10 Green Shawn J. Use of estrogenic compounds as anti-fungal agents
US20050065136A1 (en) * 2003-08-13 2005-03-24 Roby Russell R. Methods and compositions for the treatment of infertility using dilute hormone solutions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
WO2005051357A1 (en) * 2003-11-19 2005-06-09 Entremed, Inc. Antiangiogenic agents
US20100330143A1 (en) 2003-12-04 2010-12-30 University Of Utah Research Foundation Modified macromolecules and methods of making and using thereof
EP1694712A1 (de) 2003-12-04 2006-08-30 University of Utah Research Foundation Modifizierte makromoleküle und verfahren zu ihrer herstellung und verwendung
DE602005011928D1 (de) 2004-01-20 2009-02-05 Allergan Inc Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure
KR101395370B1 (ko) 2004-01-22 2014-05-14 유니버시티 오브 마이애미 국소용 코-엔자임 큐10 제형 및 그의 사용 방법
US20070004689A1 (en) * 2004-03-12 2007-01-04 Agoston Gregory E Antiangiogenic agents
CA2558014A1 (en) 2004-03-12 2005-09-29 Entremed, Inc. Antiangiogenic agents
WO2005105107A2 (en) * 2004-04-21 2005-11-10 Roby Russell R Hormone treatment of multiple sclerosis
US20050239757A1 (en) * 2004-04-21 2005-10-27 Roby Russell R Hormone treatment of macular degeneration
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244462A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US8455656B2 (en) 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US20050244465A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Drug delivery systems and methods for treatment of an eye
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
WO2005107708A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Biodegradable intravitreal tyrosine kinase inhibitors implants
US8591885B2 (en) * 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050244461A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US20050244478A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Anti-excititoxic sustained release intraocular implants and related methods
US8273383B2 (en) * 2004-05-04 2012-09-25 Children's Medical Center Corporation Methods and compositions for treatment of preeclampsia
WO2006017347A2 (en) * 2004-07-12 2006-02-16 Allergan, Inc. Opthalmic compositions and methods for treating ophthalmic conditions
US20060025390A1 (en) * 2004-07-28 2006-02-02 Roby Russell R Treatment of hormone allergy and related symptoms and disorders
TW200611909A (en) * 2004-08-04 2006-04-16 Akzo Nobel Nv Process for the preparation 2-substituted-derivatives of estrone and estradiol
TW200613316A (en) * 2004-08-26 2006-05-01 Akzo Nobel Nv Process for the preparation of estrone and/or estradiol-derivates
EP2347765B1 (de) 2004-09-24 2014-01-22 Beth Israel Deaconess Medical Center Verfahren zur Diagnose und Behandlung von Schwangerschaftskomplikationen
WO2006043965A1 (en) * 2004-10-14 2006-04-27 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
JP2008521822A (ja) * 2004-11-29 2008-06-26 エントレメッド インコーポレイテッド 抗血管形成剤を投与する方法、およびそれを用いて疾病を治療する方法
US20060148674A1 (en) * 2004-12-31 2006-07-06 Luduena Richard F Therapeutic composition
US10174070B2 (en) 2005-09-30 2019-01-08 Endece Llc 6-substituted estradiol derivatives and methods of use
US8168621B2 (en) 2005-09-30 2012-05-01 Endece, Llc 6-substituted estradiol derivatives and methods of use
US20080119447A1 (en) * 2005-09-30 2008-05-22 James Yarger 6-alkoxyalkyl estradiol derivatives and methods of use
WO2007059111A2 (en) * 2005-11-14 2007-05-24 Entremed, Inc. Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
US7627508B2 (en) * 2006-01-04 2009-12-01 S.R. Clarke, Inc. Method for tracking employees
US20070176403A1 (en) * 2006-02-01 2007-08-02 Dennis Calderone Air adjustable seat
US20070203227A1 (en) * 2006-02-24 2007-08-30 Herman Adlercreutz Isoflavan and isoflavene compounds and their use as angiogenesis inhibitors
CA2646065C (en) * 2006-03-20 2014-01-14 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
US20100285094A1 (en) * 2006-04-20 2010-11-11 University Of Utah Research Foundation Polymeric compositions and methods of making and using thereof
US8747870B2 (en) 2006-04-20 2014-06-10 University Of Utah Research Foundation Polymeric compositions and methods of making and using thereof
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
US20080032920A1 (en) * 2006-07-11 2008-02-07 Prestwich Glenn D Macromolecules modified with electrophilic groups and methods of making and using thereof
MX342437B (es) * 2006-11-30 2016-09-29 Endece Llc Derivados de estradiol de 6-alcoxialquilo y metodos de uso.
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
WO2008094665A1 (en) * 2007-01-31 2008-08-07 Entremed, Inc. Method of treating amyloidosis mediated diseases
US7911053B2 (en) * 2007-04-19 2011-03-22 Marvell World Trade Ltd. Semiconductor packaging with internal wiring bus
WO2008137599A2 (en) * 2007-05-01 2008-11-13 Evestra, Inc. 2-alkoxyestradiol analogs and pharmaceutical preparations
CA2705152C (en) 2007-11-09 2016-10-11 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
EP2323679A4 (de) 2008-07-25 2012-08-22 Univ Colorado Clip-hemmer und verfahren zur modulierung der immunfunktion
US7901904B2 (en) * 2008-10-16 2011-03-08 Naxospharma S.R.L. Method and intermediates for preparing 2-alkoxy and 2-aryloxy estrogen compounds
WO2010132498A1 (en) * 2009-05-11 2010-11-18 Oxigene, Inc. Vascular disrupting agents for treatment of polypoidal choroidal vasculopathy
DK2498783T3 (en) 2009-11-09 2018-12-10 Allergan Inc COMPOSITIONS AND PROCEDURES FOR STIMULATING HAIR GROWTH
US20120071455A1 (en) 2010-09-14 2012-03-22 Yarger James G 6-substituted demethyl-estradiol derivatives as selective er-beta agonists
EP2649095B1 (de) 2010-12-10 2021-10-06 Aleksander S. Popel Aus kollagen des typs iv abgeleitete mimetische peptide und ihre verwendung zur behandlung angiogenese- und lymphangiogenese-vermittelter krankheiten
US20120225849A1 (en) * 2011-03-01 2012-09-06 The University Of Kansas 2-Methoxyestradiol (2-ME2) Prodrug with Enhanced Bioavailability for Prophylaxis or Treatment of Cancerous or Non-Cancerous Condition
US10865383B2 (en) 2011-07-12 2020-12-15 Lineage Cell Therapeutics, Inc. Methods and formulations for orthopedic cell therapy
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
EP2956096A1 (de) 2013-02-15 2015-12-23 Allergan, Inc. Implantat mit langzeit-wirkstofffreisetzung
EP2972394A4 (de) 2013-03-15 2016-11-02 Sloan Kettering Inst Cancer Hsp90-anzielende herzbildgebung und -therapie
ES2651442T3 (es) * 2014-12-30 2018-01-26 Curadis Gmbh Esteroides C-19 para inhibir la neovascularización
US9907751B2 (en) * 2016-03-10 2018-03-06 RxOMEG Therapeutics LLC Composition and method of use of colchicine oral liquid
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
EP3576726A1 (de) 2017-02-06 2019-12-11 Massachusetts Institute Of Technology Verfahren und produkte in verbindung mit glutaminase-hemmern
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US10226423B1 (en) 2017-12-20 2019-03-12 RxOMEG Therapeutics LLC Colchicine drug-to-drug interactions
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2584271A (en) * 1948-06-19 1952-02-05 Searle & Co Steroid derivatives and method for producing the same
GB857081A (en) 1956-05-29 1960-12-29 Syntex Sa Cyclopentanophenanthrene derivatives and process for the production thereof
US3166577A (en) * 1956-05-29 1965-01-19 Syntex Corp 1, 2-dimethyl estrogens and intermediates used in the production thereof
GB857080A (en) 1956-05-29 1960-12-29 Syntex Sa Cyclopentanophenanthrene derivatives and process for the production thereof
US2846453A (en) * 1957-05-28 1958-08-05 Searle & Co Alpha-ring-acylated estrone derivatives, and corresponding alcohols, their esters, and ethers
JPS42928Y1 (de) 1964-07-25 1967-01-19
US3562260A (en) * 1965-08-23 1971-02-09 Ormonoterapia Richter Spa 2-carbonyl-estratrienes and method of their preparation
US3470218A (en) * 1966-12-27 1969-09-30 Allied Chem New 2-substituted estrogenic steroids
US3410879A (en) * 1967-04-12 1968-11-12 American Home Prod Process for preparing gonahexaenes
US3492321A (en) * 1968-01-22 1970-01-27 Syntex Corp Cyclopropenyl estra, -1,3,5(10)-trienes
US3496272A (en) * 1968-01-23 1970-02-17 American Home Prod Ester of 3-(2-propynyloxy)-estradiol
US3487155A (en) 1968-02-19 1969-12-30 Sandoz Ag Substituted estradiol alkyl ethers
DE2004516A1 (en) 1969-03-05 1970-09-10 VEB Jenapharm, Jena Thermpentic steroidal sulphonate esters
US3950437A (en) 1972-12-25 1976-04-13 Oxirane Chemical Co. Method for manufacture of dihydric phenols
GB1502635A (en) * 1974-02-27 1978-03-01 Schering Ag Process for splitting steroid ethers
JPS5265259A (en) 1975-11-27 1977-05-30 Takeda Chem Ind Ltd Synthesis of 16beta-alkylestradiol or its 17-esters
NL7613248A (nl) * 1976-11-26 1978-05-30 Akzo Nv Werkwijze voor het bereiden van nieuwe steroid- esters.
US4172132A (en) * 1977-07-26 1979-10-23 Schering Corporation 1,3,5(10),6,8,14-19-Nor-pregnahexaenes, their use as anti-psoriatic agents, and pharmaceutical formulations useful therefor
DE2757157C3 (de) 1977-12-19 1980-10-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 16 a -alkylierten Steroiden
FR2515188A1 (fr) * 1981-10-27 1983-04-29 Roussel Uclaf Nouveaux derives du 3-amino-pregn-5-ene, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant
FI830078L (fi) 1982-01-15 1983-07-16 Lilly Co Eli Askorbinsyraetrar och liknande foereningar
US5001116A (en) * 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US4994443A (en) * 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US4552758A (en) * 1983-12-20 1985-11-12 St. Jude Children's Research Hospital Human use of avian-human reassortants as vaccines for influenza A virus
US4522758A (en) * 1983-12-22 1985-06-11 Eli Lilly And Company Method of preparing 2-fluoro-17β-estradiol
US4634705A (en) * 1984-06-06 1987-01-06 Abbott Laboratories Adrenergic amidines
EP0166937B1 (de) 1984-06-06 1991-08-28 Abbott Laboratories Adrenergische Verbindungen
SU1240038A1 (ru) 1984-11-23 1996-10-27 Уральский политехнический институт им.С.М.Кирова 3-оксиэстра-1,3,5-триен-17-гидразон, обладающий гормональной и противоопухолевой активностью
US4917826A (en) 1985-10-18 1990-04-17 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
JPS62135472A (ja) 1985-12-10 1987-06-18 Yakult Honsha Co Ltd 新規な１，２−ビス−３，５−ジオキソピペラジニルエタン誘導体
US4743597A (en) * 1986-01-27 1988-05-10 Javitt Norman B Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases
JP2544136B2 (ja) 1986-05-23 1996-10-16 第一製薬株式会社 硫酸化多糖体ｄｓ４１５２を含有する血管新生抑制剤及び抗腫瘍剤
DE3625315A1 (de) 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
JP2517561B2 (ja) 1986-10-03 1996-07-24 新技術事業団 カテコ−ルエストロゲンのイムノアツセイキツド
US5352664A (en) 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
ATE77387T1 (de) 1987-04-16 1992-07-15 Upjohn Co Zyklische kohlenwasserstoffe mit aminoalkylseitenkette.
US4808402A (en) * 1987-05-29 1989-02-28 Northwestern University Method and compositions for modulating neovascularization
US5135919A (en) * 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
JPH01240038A (ja) 1988-03-19 1989-09-25 Fujitsu Ltd ピーク値比較型タイミング再生方式
WO1990015816A1 (en) 1989-06-16 1990-12-27 The Upjohn Company Suramin type compounds and angiostatic steroids to inhibit angiogenesis
US4990538A (en) * 1989-08-23 1991-02-05 Harris Adrian L Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
JPH03240726A (ja) 1990-02-15 1991-10-28 Fujisawa Pharmaceut Co Ltd 化学療法効果増強剤
JPH0446120A (ja) 1990-06-11 1992-02-17 Kyowa Hakko Kogyo Co Ltd 血管新生抑制剤
IT1247827B (it) 1991-02-05 1995-01-02 Erba Carlo Spa Benzoil carbinolo e suoi esteri, utili come inibitori dell'angiogenesi
WO1993003729A1 (en) * 1991-08-12 1993-03-04 Research Corporation Technologies, Inc. N-substituted phenoxazines for treating multidrug resistant cancer cells
US6011024A (en) * 1991-08-28 2000-01-04 Imperial College Of Science Technology & Medicine Steroid sulphatase inhibitors
EP1236470A3 (de) * 1991-11-22 2004-09-01 Alcon Laboratories, Inc. Angiostatische Steroide
NZ246242A (en) 1991-12-02 1996-01-26 Cor Therapeutics Inc Inhibiting immunoglobulins acting on beta-platelet derived growth factor (pdgf)
GB9207437D0 (en) 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
DE4235657A1 (de) * 1992-10-22 1994-06-23 Schering Ag Verfahren zum Alkylieren von Östronderivaten
KR960700045A (ko) * 1993-01-11 1996-01-19 가자마 하치자에몽 혈관신생 저해제 및 신규 화합물
ES2204919T3 (es) 1993-05-27 2004-05-01 Entremed, Inc. Composiciones y procedimientos de tratamiento del cancer y de enfermedades hiperproliferativas.
US5643900A (en) * 1993-07-02 1997-07-01 Fotsis; Theodore Method for treatment of pathological conditions associated with angiogenesis and preparation therefor
US5886026A (en) * 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
ATE355379T1 (de) * 1994-04-26 2006-03-15 Childrens Medical Center Angiostatin und verfahren zu seiner nutzung zur vermeidung der angiogenese
US5837682A (en) * 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
GB9418067D0 (en) * 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
US5521168A (en) * 1994-10-13 1996-05-28 Alcon Laboratories, Inc. Estrogen metabolites for lowering intraocular pressure
US5861372A (en) * 1996-02-22 1999-01-19 The Children's Medical Center Corporation Aggregate angiostatin and method of use
US5854205A (en) * 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US5854221A (en) * 1996-12-12 1998-12-29 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use
AU2103097A (en) * 1996-03-15 1997-10-10 Zeneca Limited Cinnoline derivatives and use as medicine
CN1245982C (zh) * 1996-05-09 2006-03-22 阿姆瑞德手术有限公司 哮喘和气道疾病的治疗
US5958892A (en) * 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
US5763432A (en) * 1997-01-29 1998-06-09 Sri International Steriod inhibitors of estrone sulfatase and associated pharmaceutical compositions and methods of use
US6051726A (en) * 1997-03-13 2000-04-18 Pharm-Eco Laboratories, Inc. Synthesis of 2-alkoxyestradiols
US6136992A (en) * 1997-03-13 2000-10-24 The United States Of America As Represented By The Department Of Health And Human Services 2-alkoxy estradiols and derivatives thereof
CA2208916A1 (en) 1997-07-03 1999-01-03 Hyal Pharmaceutical Corporation Promotion of wound healing utilizing steroids having reduced deterioroussystemic side effects typical of glucocorticoids, mineralocorticoids andsex steroids
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
EP1027045A4 (de) 1997-10-31 2004-12-08 Arch Dev Corp Methoden und zusammenstellungen zur regelierung des s-alpha-reduktaseaktivität
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6046186A (en) 1997-12-24 2000-04-04 Sri International Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use
JPH11209322A (ja) 1998-01-27 1999-08-03 Kao Corp イソバニリルアルコール誘導体
ID28791A (id) 1998-08-07 2001-07-05 Endorech Inc PENGHAMBATAN DEHIDROGENASE HIDROKSISTEROID 3α TIPE 3
EP1124545B1 (de) * 1998-08-11 2004-12-15 EntreMed, Inc. Verwendung von 2-methoxyestradiol als fungizide
WO2000010552A2 (en) 1998-08-24 2000-03-02 Global Vascular Concepts, Inc. Use of anti-angiogenic agents for inhibiting vessel wall injury
US6284789B1 (en) * 1998-09-04 2001-09-04 The Research Foundation Of State University Of New York Formation and composition of new optically active compounds
WO2000025780A1 (en) * 1998-10-29 2000-05-11 Bristol-Myers Squibb Company Compounds derived from an amine nucleus that are inhibitors of impdh enzyme
US6358940B1 (en) * 1999-09-07 2002-03-19 Rutgers, The State University Modified 2-Alkoxyestradiol derivatives with prolonged pharmacological activity

Also Published As

Publication number Publication date
CA2168850A1 (en) 1995-02-16
US20030055029A1 (en) 2003-03-20
DK0713393T3 (da) 2006-05-08
US20030236408A1 (en) 2003-12-25
CA2168850C (en) 2007-01-02
EP0713393A4 (de) 2000-10-25
JPH09501433A (ja) 1997-02-10
EP1927359A3 (de) 2008-06-11
EP1640009B1 (de) 2008-10-15
ES2255704T3 (es) 2006-07-01
US20030096800A1 (en) 2003-05-22
DE69435151D1 (de) 2008-11-27
EP1640009A1 (de) 2006-03-29
ATE313327T1 (de) 2006-01-15
DE69434584T2 (de) 2006-07-13
US5892069A (en) 1999-04-06
US7012070B2 (en) 2006-03-14
EP0713393A1 (de) 1996-05-29
US5661143A (en) 1997-08-26
HK1014504A1 (en) 1999-09-30
HK1089387A1 (en) 2006-12-01
PT1640009E (pt) 2008-12-22
JP2008120839A (ja) 2008-05-29
WO1995004535A1 (en) 1995-02-16
US7109187B2 (en) 2006-09-19
JP2008120840A (ja) 2008-05-29
EP1927359A2 (de) 2008-06-04
DK1640009T3 (da) 2009-01-26
US20060183727A1 (en) 2006-08-17
DE69434584D1 (de) 2006-01-26
ES2315763T3 (es) 2009-04-01
EP0713393B1 (de) 2005-12-21
AU7450994A (en) 1995-02-28
US7291610B2 (en) 2007-11-06
US5504074A (en) 1996-04-02
US6528676B1 (en) 2003-03-04

Similar Documents

Publication Publication Date Title
ATE411029T1 (de) Estrogene als antimitotika
DE69106603D1 (de) Fluorhaltiges Copolymer und dieses enthaltende härtbare Zusammensetzung.
MX9102728A (es) Resina de mesofase solvatada y metodo para su formacion.
DE69432359D1 (de) Katheter mit kleinem durchmesser und hohem drehmoment
DE69431810D1 (de) Halbleiterelement und Halbleiterspeicher-Bauelement, das dieses verwendet
FI941577L (fi) Polyeteenikalvoja joilla on matala takertumisvoima
DE69430778D1 (de) Spannungstromdifferentialwandler vom MOS-Typ
BR9706996A (pt) Esteres com elevadas estabilidade e baixos teores de metal à base de 3,5,5,trimetil-1-hexanol
DE59400380D1 (de) Polytetrafluorethylen-Mikropulver, ihre Herstellung und Verwendung
FI914393A0 (fi) Anordning foer soenderdelning av konkrement i kroppen pao en patient.
FR2713423B1 (fr) Codeur et décodeur différentiels pour la modulation MDP-8 codée en treillis par l'approche pragmatique.
EP0410074A3 (en) Radial load reducing device, and sliding bearing and screw compressor using the device
DE69528845D1 (de) N-bit umsetzer mit n-1-grössenverstärkern und n-vergleichern
FR2713444B1 (fr) Composition liquide désinfectante et ses utilisations.
DE69422126D1 (de) Flüssigkristallzusammensetzung, Flüssigkristallvorrichtung und diese verwendende Vorrichtung
EP0659894A3 (de) Legierung auf Stahlbasis mit hohem Modul und Verfahren zu deren Herstellung.
DE69107566D1 (de) Flurförderfahrzeug mit Fahrerstandplatz und erhöhter Stabilität.
SE9200762D0 (sv) New topical use
IT1270823B (it) Polisaccaridi ad elevata attivita' antitrombotica e anticoagulante
DE69423954D1 (de) Hartbäres Silizium-enthaltendes Polymer und härtbare Zusammensetzung auf Basis dieses Polymeres
DE59100375D1 (de) Abtastvorrichtung sowie Verwendung derselben.
DE69202566D1 (de) Schwingpupille-autofokusverfahren und geraet.
ATE114464T1 (de) Verwendung von zofenopril zur herstellung von medikamenten gegen rheumatoide arthritis.
Rogers Mutation, mind and epistemology; an examination of the concept of territoriality in humans as an informational and evolutionary phenomenon.
FR2676677B1 (fr) Support d'etau pivotant et orientable.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1640009

Country of ref document: EP

REN Ceased due to non-payment of the annual fee